{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:16:14Z","timestamp":1793866574785,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.lungcan.2026.109501","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:58:46Z","timestamp":1781827126000},"page":"109501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Durvalumab plus etoposide\u2013platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD"],"prefix":"10.1016","volume":"218","author":[{"given":"Isamu","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianus J.","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Piotrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena A.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Rosario","family":"Garcia Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Cetnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-0523","authenticated-orcid":false,"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-193X","authenticated-orcid":false,"given":"Yoshimasa","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5418-2545","authenticated-orcid":false,"given":"Paul E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-5159","authenticated-orcid":false,"given":"Kwan Ho","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6349-0332","authenticated-orcid":false,"given":"Jonathan M.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109501_b0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.109501_b0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109501_b0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109501_b0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109501_b0025","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non\u2013small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0030","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0035","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109501_b0040","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109501_b0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109501_b0050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/cancers17030459","article-title":"Optimizing osimertinib for NSCLC: targeting resistance and exploring combination therapeutics","volume":"17","author":"Liao","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109501_b0055","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109501_b0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0065","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.23.01435","article-title":"Systemic therapy for small-cell lung cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline","volume":"41","author":"Khurshid","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0070","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1308313","article-title":"Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0080","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2018.08.2028","article-title":"A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics","volume":"14","author":"Ferrer","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0085","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109501_b0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0095","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109501_b0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109501_b0110","unstructured":"National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology, Non-small cell lung cancer; Version 4.2021, Available at URL: https:\/\/www.nccn.org. Accessed on 05 August 2025."},{"key":"10.1016\/j.lungcan.2026.109501_b0115","doi-asserted-by":"crossref","first-page":"108936","DOI":"10.18632\/oncotarget.22426","article-title":"Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing","volume":"8","author":"Ito","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2026.109501_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115065","article-title":"Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy","volume":"213","author":"Saalfeld","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109501_b0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cllc.2021.06.006","article-title":"Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced\/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD)","volume":"22","author":"Yu","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109501_b0130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/pst.1746","article-title":"Decision-making in early clinical drug development","volume":"15","author":"Frewer","year":"2016","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.lungcan.2026.109501_b0135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ctrv.2017.07.007","article-title":"Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: a systematic review and pooled analysis","volume":"59","author":"Roca","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2026.109501_b0140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2021.03.006","article-title":"Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: a multicenter retrospective study","volume":"155","author":"Wang","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109501_b0145","first-page":"452","article-title":"Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy, Transl Lung","volume":"11","author":"Yu","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109501_b0150","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 EXTENTORCH randomized clinical trial","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0160","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0165","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2026.109501_b0170","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109501_b0175","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer\u2014a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0180","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0185","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2012resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0190","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109501_b0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2022.02.006","article-title":"Histologic transformation of epidermal growth factor receptor-mutated lung cancer","volume":"166","author":"Fujimoto","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109501_b0200","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.3390\/cancers13184641","article-title":"Histologic transformation in EGFR-mutant lung adenocarcinomas: mechanisms and therapeutic implications","volume":"13","author":"Pathak","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109501_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189413","article-title":"Histological transformation in lung cancer: mechanisms, clinical characteristics, and therapeutic approaches","volume":"1880","author":"Liu","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.lungcan.2026.109501_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103044","article-title":"Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming","volume":"141","author":"Wang","year":"2025","journal-title":"Cancer Treat. Rev."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:27:29Z","timestamp":1790342849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"alternative-id":["S0169500226005623"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109501","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab plus etoposide\u2013platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109501"}}